MEDIVIR AB Company Profile
Medivir develops drugs against major, widespread diseases, based on proteases as the target enzyme. Its objective is to be a sustainable and profitable research-based pharmaceutical company with products on the market that it has developed in-house. Medivir was founded in 1988.In Sweden, the company is located in Huddinge, near Stockholm, and in the UK, at Chesterford Research Park, Essex.The group comprises Medivir AB, its subsidiary Medivir UK Ltd., Medivir HIV Franchise AB and Medivir Personal AB.
Medivir was listed on the Stockholm Stock Exchange O-list in 1996.
Medivir had a staff headcount of 133 on 31 December 2005.
In December 2005, Medivir's board of directors decided to focus operations, and to take its ME-609 (labial herpes) project into phase III studies towards market registration. At this point, Medivir HIV Franchise AB was incorporated, whose purpose is to divest Medivir's polymerase-based projects against HIV, hepatitis B and shingles, and to concentrate research within the parent company on protease-based projects.
Location
Lunastigen7
Huddinge
SE-141 44
Sweden
Contact
Phone: 46 (0)8 5468 3100
Fax: 46 (0)8 5468 3199
Email: medivir@medivir.se
News Articles
Regulatory News: Medivir (STO:MVIR-B) Annual Report 2012 is now available at the company's website: www.medivir.com. Annual Report 2012 http://www.medivir...
Medivir presents at the Jefferies Global Healthcare Conference
Regulatory News: Medivir (STO:MVIR-B) will participate in, and present at, the Jefferies 2013 Global Healthcare Conference in New York. Slides from the presentation will be available on Medivir's ...
Medivir partners with Swedish university for antibiotics
Medivir AB (SSE:MVIR B) partnered with the Swedish University of Agricultural Sciences to discover and develop antibiotics against drug-resistant bacteria. Medivir will be responsible for development...
Medivir strengthens its R&D organization
Regulatory News: Medivir AB (OMX: MVIR) today announced that the company will divide its current R&D organization into two parts, Discovery Research and Development, and strengthen the R&D leaders...
[Medivir] gets early-stage antiviral assets from [Novadex]
Infectious disease-focused [Medivir AB] has acquired preclinical antiviral assets from fellow Swedish biotech [Novadex Pharmaceuticals AB]. Novadex receives undisclosed money up front plus potential...
Janssen submits simeprevir NDA
The Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ) submitted an NDA to FDA for simeprevir (TMC435) to treat HCV genotype 1 infection. The submission triggers a EUR 10 million...
Medivir strengthens hepatitis C platform
Medivir AB, announced today that it has acquired preclinical research stage assets from Novadex Pharmaceuticals AB. The acquisition includes intellectual property and prodrug technologies in order to...
Medivir Submits New Drug Application for Simeprevir
Medivir AB today announced that a new drug application (NDA) has been filed with the U.S. Food and Drug Administration (FDA) seeking approval for simeprevir. The filing is based on phase III data in t...
Drugs and Medications
Xerese [Meda Pharmaceuticals Inc.]
These highlights do not include all the information needed to use XERESE™ (acyclovir and hydrocortisone) Cream 5%/1% safely and effectively. See full prescribing information for XERESE. XERESE™ (a...
PubMed Articles
Cathepsin S inhibitors: WO2010070615.
This article evaluates a patent application of the company Medivir (SE/UK) describing the synthesis of dipeptide-derived α-ketoamides containing a propylene glycine moiety in P1 as selective inhibito...
Novel NS3/4A protease inhibitors comprising quinazoline derivatives as P2 substituent were synthesized. High potency inhibitors displaying advantageous PK properties have been obtained through the opt...
Clinical Trials
None
Companies
Medivir is an emerging research-based pharmaceutical company focused on infectious diseases.
Medivir develops drugs against major, widespread diseases, based on proteases as the target enzyme. Its objective is to be a sustainable and profitable research-based pharmaceutical company with produ...
The group consists of Medivir AB, the subsidiaries Medivir UK Ltd., CCS AB and Medivir Personal AB, as well as the second-tier subsidiaries CCS (UK) Ltd. and Nordic Care Sweden AB. At year end 2001, t...
More Information about "MEDIVIR AB" on BioPortfolio
We have published hundreds of MEDIVIR AB news stories on BioPortfolio along with dozens of MEDIVIR AB Clinical Trials and PubMed Articles about MEDIVIR AB for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of MEDIVIR AB Companies in our database. You can also find out about relevant MEDIVIR AB Drugs and Medications on this site too.
